Clinical trial
Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes
NCT06471946 is registered in ClinicalTrials.gov with Navy General Hospital, Beijing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes
- Lead sponsor
- Navy General Hospital, Beijing
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- October 1, 2024
- Completion date
- September 1, 2030
- Enrollment
- 54 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
higher-risk myelodysplastic syndromes